Since new FDA Commissioner Scott Gottlieb announced the FDA precertification program, the agency has been moving full speed ahead to re-invent its process for clearing digital health products. Pre-Cert will emphasize a focus on evaluating “standards of excellence” for the company or firm, rather than focusing on specific products. The idea is that trusted shops will be able to iterate technologies at their own pace.
While many support the program, critical voices have also begun to emerge. Bradley Merrill Thompson, a member of the firm at Epstein Becker Green who also helps lead the Clinical Decision Support Coalition, laid out some of his own concerns in a recent editorial.
So we’re asking readers what you think.
Focus on Innovation
In September, we take a deep dive into the cutting-edge development and disruption of healthcare innovation.